Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-Current Assets (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Non-Current Assets for 8 consecutive years, with $81.7 million as the latest value for Q1 2026.

  • Quarterly Non-Current Assets rose 59.21% to $81.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $321.1 million through Feb 2026, up 46.2% year-over-year, with the annual reading at $81.3 million for FY2025, 62.78% up from the prior year.
  • Non-Current Assets for Q1 2026 was $81.7 million at Nurix Therapeutics, up from $81.3 million in the prior quarter.
  • The five-year high for Non-Current Assets was $157.2 million in Q1 2022, with the low at $40.2 million in Q3 2023.
  • Average Non-Current Assets over 5 years is $76.0 million, with a median of $76.2 million recorded in 2025.
  • The sharpest move saw Non-Current Assets soared 83.06% in 2022, then tumbled 61.47% in 2023.
  • Over 5 years, Non-Current Assets stood at $98.3 million in 2022, then plummeted by 38.87% to $60.1 million in 2023, then decreased by 16.87% to $50.0 million in 2024, then surged by 62.78% to $81.3 million in 2025, then grew by 0.52% to $81.7 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $81.7 million, $81.3 million, and $81.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.